Therapeutics Initiative’s Best Evidence Webinar: Drug-drug interactions in older adults with polypharmacy prescribed nirmatrelvir-ritonavir for the treatment of COVID-19
December 14 @ 12:00 pm - 1:00 pmFree
Dr. Marnie Wilson is a Clinical Assistant Professor of Medicine (Internal Medicine) and a fellow in Critical Care Medicine at the University of British Columbia. Her research interest is in deprescription and the implementation of deprescription interventions, particularly in hospitalized patients and patients with complex multimorbidity.
Dr Emily G. McDonald is an Associate Professor of Medicine at McGill University, the Associate Chair of Quality and Safety for the Department of Medicine and a medication safety scientist at the research institute of the McGill University Health Centre. Dr. McDonald is also the Scientific Director of the Canadian Deprescribing Network and the founder of MedSafer, a software to guide deprescribing for older adults with polypharmacy.
DATE: Wednesday, December 14, 2022
TIME: 12:00 – 13:00 Pacific Time PDT
WHERE: This is a free virtual event. After you register, you will receive a confirmation email with the connection details.
CME CREDITS: MainPro+/MOC Section 1 credits: 1.0. Those who register, attend the webinar and complete the evaluation will receive their certificate.
By the end of the presentation, attendees will be able to:
Understand the population where nirmatrelvir-ritonavir has been shown to be effective at reducing serious outcomes and identity the populations where nirmatrelvir-ritonavir is commonly prescribed.
Name the top 5 drug-drug interactions in older adults with polypharmacy who are prescribed nirmatrelvir-ritonavir.
Identify medication management strategies for common drug-drug interactions, including the risks and benefits of pursuing (or not) treatment with nirmatrelvir-ritonavir vs deprescribing potentially inappropriate and interacting medications.
Recognize where there is a lack of evidence and where more research is needed.